My research aims to elucidate the genetic and epigenetic factors in cancer and to define the precise molecular and cellular events in cancer initiation and progression. The professional interests in my lab is: RNA modification editing, CAR-T cell therapy and screening of small molecule drugs to promote tumor cell immunotherapy. The translational objective of my research is to develop first-in-class cell therapy and cancer immunotherapeutic agents.
Research Fundings
(1) Natural Science Foundation of Guangdong Province-Key Project; Title: "Efficient integration of microRNA and two-way optimization of CAR-T cell therapy strategy research", project approval number: "2017A030311004",
(2) National Natural Science Foundation of China; Title: " Preparation and functional research of miR-CAR-T cells "; Project approval number: "81773249"; (3) Guangzhou Science and Technology Project; name "Synthetic PLGA-anti-miR-301a in the treatment of panIN precancerous lesions of the panIN mechanism"; project approval number: "201707010139";
(4) National Natural Science Foundation of China; Title: "Research on miR-301a regulating NF-kB/Stat3-mediated non-controllable pancreatitis-mediated malignant transformation mechanism and targeted therapy"; Project approval number: "81572399" ;
(5) National Natural Science Foundation of China; title: "microRNA-21-mediated apoptosis-necrosis transformation mechanism and its role in acute necrotizing pancreatitis", project approval number: "81270547"
(6) Guangdong Science and Technology Project-International Cooperation Field; Title: "Research on the Mechanism of Anti-miR-21 Inhibiting SIRS in the Treatment of Multiple Organ Dysfunction Syndrome", project approval number: "2014050503062"
(7) Natural Science Foundation of Guangdong Province-Free Application Project; Title: "The Mechanism and Application of miR-301 Regulating Stat3/NF-kB Signal Pathway in Lung Cancer and Its Application", Project Approval Number: "2015A030313372",
Publications
Ming Liu, Xu Wang, Wei Li, Xinfang Yu, Pedro Flores-Villanueva, Zijun Y Xu-Monette, Ling Li, Mingzhi Zhang, Ken H Young, Xiaodong Ma*, Yong Li*. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020 Aug 13;9(8):72
Jiexuan Wang#, Xun Li#, Mingtian Zhong#, Yansheng Wang, Liming Zou, Miaomiao Wang, Xiaoli Gong, Xinjie Wang, Chengzhi Zhou*, Xiaodong Ma*, Ming Liu*. miR-301a Suppression within Fibroblasts Limits the Progression of Fibrosis through the TSC1/mTOR Pathway. Mol Ther Nucleic Acids. 2020 May 26;21:217-228.
Xiaoli Gong, Liming Zou, Miaomiao Wang, Yingheng Zhang, Shuxian Peng, Mingtian Zhong, Jiankui Zhou, Xun Li*, Xiaodong Ma*. Gramicidin inhibits cholangiocarcinoma cell growth by suppressing EGR4. Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):53-59..
Xinjie Wang, Zhiwei Liu, GuangLei Li, Lu Dang, Shisheng Huang, Lei He, Yu’e Ma, Cong Li, Ming Liu, Guang Yang, Xingxu Huang, FeiZhou*, Xiaodong Ma*. Efficient Gene Silencing by Adenine Base Editor Mediated Start Codon Mutation. Molecular Therapy. 2019 Nov 29. pii: S1525-0016(19)30548-9..
Wang L, Deng Q, Hu H, Liu M, Gong Z, Zhang S, Xu-Monette ZY, Lu Z, Young KH, Ma X*, Li Y*. Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice. J Hematol Oncol. 2019 Jul 5;12(1):70. Xun Li#, Mingtian Zhong#, Jiexuan Wang#, Lei Wang, Zhanwen Lin, Zhi Cao, Zhujuan Huang, , Fengxue Zhang, Yong Li, Ming Liu*, Xiaodong Ma*. miR-301a promotes lung tumorigenesis by suppressing Runx3. Molecular Cancer, 2019 May 23;18(1):99.
Xun Li#, Zhanwen Lin#, Lei Wang #, Qin Liu, Zhi Cao, Zhujuan Huang, Mingtian Zhong, Shuxian Peng, Yingheng Zhang, Yong Li, Xiaodong Ma*. RNA-Seq Analyses of the Role of miR-21 in Acute Pancreatitis. Cellular Physiology and Biochemistry, 2018;51(5):2198-2211.
Mingtian Zhong#, Zhujuan Huang#, Lei Wang#, Zhanwen Lin, Zhi Cao, Xun Li, Fengxue Zhang, Hongqi Wang, Yong Li*, Xiaodong Ma*. Malignant Transformation of Human Bronchial Epithelial Cells Induced by Arsenic through STAT3/miR-301a/SMAD4 Loop.Scientific Reports. 2018.09: 13291.